Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.

The May meeting thus serves as a ratification of BioNTech's new architecture for the post-pandemic era. The votes will legitimize the structural and financial framework designed to bridge the company ...

BioNTech hopes its purchase of CureVac will help boost its research into cancer treatments - Copyright AFP Sam PANTHAKY BioNTech hopes its purchase of CureVac will ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...

The German biotechnology company currently employs 85 people at its manufacturing plant in Tuas.

(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its ...

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed ...

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.